Standard

Hepatitis B Virus Genotypes in Patients with Hepatitis D as Determined by the Panel of Their Own Development of Monoclonal Antibodies. / Bezuglova, L. V.; Isaeva, O. V.; Karlsen, A. A. et al.

In: Molecular Genetics, Microbiology and Virology, Vol. 37, No. 2, 06.2022, p. 91-98.

Research output: Contribution to journalArticlepeer-review

Harvard

Bezuglova, LV, Isaeva, OV, Karlsen, AA, Ilchenko, LY, Sleptsova, SS, Saryglar, AA, Poryvaeva, VA, Mosina, YD, Agafonova, OA, Mogilnykh, AK, Kyuregyan, KK, Mikhailov, MI, Netesov, SV & Netesova, IG 2022, 'Hepatitis B Virus Genotypes in Patients with Hepatitis D as Determined by the Panel of Their Own Development of Monoclonal Antibodies', Molecular Genetics, Microbiology and Virology, vol. 37, no. 2, pp. 91-98. https://doi.org/10.3103/S0891416822020033

APA

Bezuglova, L. V., Isaeva, O. V., Karlsen, A. A., Ilchenko, L. Y., Sleptsova, S. S., Saryglar, A. A., Poryvaeva, V. A., Mosina, Y. D., Agafonova, O. A., Mogilnykh, A. K., Kyuregyan, K. K., Mikhailov, M. I., Netesov, S. V., & Netesova, I. G. (2022). Hepatitis B Virus Genotypes in Patients with Hepatitis D as Determined by the Panel of Their Own Development of Monoclonal Antibodies. Molecular Genetics, Microbiology and Virology, 37(2), 91-98. https://doi.org/10.3103/S0891416822020033

Vancouver

Bezuglova LV, Isaeva OV, Karlsen AA, Ilchenko LY, Sleptsova SS, Saryglar AA et al. Hepatitis B Virus Genotypes in Patients with Hepatitis D as Determined by the Panel of Their Own Development of Monoclonal Antibodies. Molecular Genetics, Microbiology and Virology. 2022 Jun;37(2):91-98. doi: 10.3103/S0891416822020033

Author

Bezuglova, L. V. ; Isaeva, O. V. ; Karlsen, A. A. et al. / Hepatitis B Virus Genotypes in Patients with Hepatitis D as Determined by the Panel of Their Own Development of Monoclonal Antibodies. In: Molecular Genetics, Microbiology and Virology. 2022 ; Vol. 37, No. 2. pp. 91-98.

BibTeX

@article{f6c2dea6173b4edaa3af74826dca0cdd,
title = "Hepatitis B Virus Genotypes in Patients with Hepatitis D as Determined by the Panel of Their Own Development of Monoclonal Antibodies",
abstract = "Direct genotyping of hepatitis B virus (HBV) in samples from patients with hepatitis delta can be impossible due to an undetectable concentration of HBV DNA. A sufficient amount of surface HBV protein (HBsAg) in such samples makes it possible to determine HBV genotype using enzyme-linked immunosorbent assay (ELISA) of this antigen with a panel of monoclonal antibodies (MABs). The purpose of this paper is to compare the results of HBV genotyping using an in-house MAB panel with the results of molecular analysis of samples from patients with chronic hepatitis B (CHB) and the determination of HBV genotypes in samples from patients with hepatitis delta. A total of 122 serum samples from CHB patients from Yakutia and 211 serum samples from hepatitis delta patients from Yakutia (12 samples) and Tuva (199 samples) were collected. HBV serotypes/genotypes were determined by ELISA using developed reagents. The molecular methods included the isolation of HBV DNA, amplification of the S gene region (713 nt), and phylogenetic analysis of the nucleotide sequences. In a group of samples from CHB patients positive for HBV DNA (86 samples), 95% (82/86) valid results were obtained using our MAB kit. The following genotypes were identified: A, 32 (39%); C, 3 (4%); and D, 47 (57%). The results of HBV genotyping using two methods were identical for 81/82 (99%) samples. HBV genotyping using developed reagents provided 96.2% (203/211) of valid results in samples from patients with hepatitis delta compared to 3.8% of such results obtained using the standard molecular technic (p < 0.001). The following HBV genotypes were identified: A, 17 samples (8.4%), and D, 186 samples (91.6%). The developed test with MAB panel allows one to reliably determine HBV genotype and has advantages over standard molecular methods for HBV genotyping in patients with hepatitis delta.",
keywords = "enzyme-linked immunosorbent assay, genotype, HBsAg, hepatitis B virus, hepatitis D, monoclonal antibodies",
author = "Bezuglova, {L. V.} and Isaeva, {O. V.} and Karlsen, {A. A.} and Ilchenko, {L. Y.} and Sleptsova, {S. S.} and Saryglar, {A. A.} and Poryvaeva, {V. A.} and Mosina, {Ya D.} and Agafonova, {O. A.} and Mogilnykh, {A. K.} and Kyuregyan, {K. K.} and Mikhailov, {M. I.} and Netesov, {S. V.} and Netesova, {I. G.}",
note = "Funding Information: Thos work was financially supported by АО Vector-Best, as well as partially supported by an FSUS-2020-0035 grant for basic research of Novosibirsk State University and the TOP-100 Russian Universities Competitiveness Improvement Program. Publisher Copyright: {\textcopyright} 2022, Allerton Press, Inc.",
year = "2022",
month = jun,
doi = "10.3103/S0891416822020033",
language = "English",
volume = "37",
pages = "91--98",
journal = "Molecular Genetics, Microbiology and Virology",
issn = "0891-4168",
publisher = "Allerton Press Inc.",
number = "2",

}

RIS

TY - JOUR

T1 - Hepatitis B Virus Genotypes in Patients with Hepatitis D as Determined by the Panel of Their Own Development of Monoclonal Antibodies

AU - Bezuglova, L. V.

AU - Isaeva, O. V.

AU - Karlsen, A. A.

AU - Ilchenko, L. Y.

AU - Sleptsova, S. S.

AU - Saryglar, A. A.

AU - Poryvaeva, V. A.

AU - Mosina, Ya D.

AU - Agafonova, O. A.

AU - Mogilnykh, A. K.

AU - Kyuregyan, K. K.

AU - Mikhailov, M. I.

AU - Netesov, S. V.

AU - Netesova, I. G.

N1 - Funding Information: Thos work was financially supported by АО Vector-Best, as well as partially supported by an FSUS-2020-0035 grant for basic research of Novosibirsk State University and the TOP-100 Russian Universities Competitiveness Improvement Program. Publisher Copyright: © 2022, Allerton Press, Inc.

PY - 2022/6

Y1 - 2022/6

N2 - Direct genotyping of hepatitis B virus (HBV) in samples from patients with hepatitis delta can be impossible due to an undetectable concentration of HBV DNA. A sufficient amount of surface HBV protein (HBsAg) in such samples makes it possible to determine HBV genotype using enzyme-linked immunosorbent assay (ELISA) of this antigen with a panel of monoclonal antibodies (MABs). The purpose of this paper is to compare the results of HBV genotyping using an in-house MAB panel with the results of molecular analysis of samples from patients with chronic hepatitis B (CHB) and the determination of HBV genotypes in samples from patients with hepatitis delta. A total of 122 serum samples from CHB patients from Yakutia and 211 serum samples from hepatitis delta patients from Yakutia (12 samples) and Tuva (199 samples) were collected. HBV serotypes/genotypes were determined by ELISA using developed reagents. The molecular methods included the isolation of HBV DNA, amplification of the S gene region (713 nt), and phylogenetic analysis of the nucleotide sequences. In a group of samples from CHB patients positive for HBV DNA (86 samples), 95% (82/86) valid results were obtained using our MAB kit. The following genotypes were identified: A, 32 (39%); C, 3 (4%); and D, 47 (57%). The results of HBV genotyping using two methods were identical for 81/82 (99%) samples. HBV genotyping using developed reagents provided 96.2% (203/211) of valid results in samples from patients with hepatitis delta compared to 3.8% of such results obtained using the standard molecular technic (p < 0.001). The following HBV genotypes were identified: A, 17 samples (8.4%), and D, 186 samples (91.6%). The developed test with MAB panel allows one to reliably determine HBV genotype and has advantages over standard molecular methods for HBV genotyping in patients with hepatitis delta.

AB - Direct genotyping of hepatitis B virus (HBV) in samples from patients with hepatitis delta can be impossible due to an undetectable concentration of HBV DNA. A sufficient amount of surface HBV protein (HBsAg) in such samples makes it possible to determine HBV genotype using enzyme-linked immunosorbent assay (ELISA) of this antigen with a panel of monoclonal antibodies (MABs). The purpose of this paper is to compare the results of HBV genotyping using an in-house MAB panel with the results of molecular analysis of samples from patients with chronic hepatitis B (CHB) and the determination of HBV genotypes in samples from patients with hepatitis delta. A total of 122 serum samples from CHB patients from Yakutia and 211 serum samples from hepatitis delta patients from Yakutia (12 samples) and Tuva (199 samples) were collected. HBV serotypes/genotypes were determined by ELISA using developed reagents. The molecular methods included the isolation of HBV DNA, amplification of the S gene region (713 nt), and phylogenetic analysis of the nucleotide sequences. In a group of samples from CHB patients positive for HBV DNA (86 samples), 95% (82/86) valid results were obtained using our MAB kit. The following genotypes were identified: A, 32 (39%); C, 3 (4%); and D, 47 (57%). The results of HBV genotyping using two methods were identical for 81/82 (99%) samples. HBV genotyping using developed reagents provided 96.2% (203/211) of valid results in samples from patients with hepatitis delta compared to 3.8% of such results obtained using the standard molecular technic (p < 0.001). The following HBV genotypes were identified: A, 17 samples (8.4%), and D, 186 samples (91.6%). The developed test with MAB panel allows one to reliably determine HBV genotype and has advantages over standard molecular methods for HBV genotyping in patients with hepatitis delta.

KW - enzyme-linked immunosorbent assay

KW - genotype

KW - HBsAg

KW - hepatitis B virus

KW - hepatitis D

KW - monoclonal antibodies

UR - http://www.scopus.com/inward/record.url?scp=85139235647&partnerID=8YFLogxK

UR - https://www.mendeley.com/catalogue/fe79b94c-b934-324d-a8b6-fa0f1390bbe9/

U2 - 10.3103/S0891416822020033

DO - 10.3103/S0891416822020033

M3 - Article

AN - SCOPUS:85139235647

VL - 37

SP - 91

EP - 98

JO - Molecular Genetics, Microbiology and Virology

JF - Molecular Genetics, Microbiology and Virology

SN - 0891-4168

IS - 2

ER -

ID: 38159435